CTLA4 and neoplasm: To evaluate the effects of CTLA-4 blockade in our lymphocyte-depleted TC-1 tumor model, we treated tumors with RT and either vehicle or a blocking antibody against CTLA-4 that does not deplete Tregs (52, 53) on successive days.